Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO
JNCI Journal of the National Cancer InstitutePublished 5 June 2002Open access
David Euhus, Kristin C. Smith, Linda Robinson, Amy Stucky, Olufunmilayo I. Olopade, Shelly Cummings
Citations153
SJR quartileQ1
SJR score5.70
SNIP2.66
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Sensitivity for identifying BRCA gene mutation carriers is similar for experienced risk counselors and the computer model, BRCAPRO, at identifying families likely to carry a BRCa gene mutation.
Abstract
Sensitivity for identifying BRCA gene mutation carriers is similar for experienced risk counselors and the computer model BRCAPRO. Because the computer model consistently demonstrated superior specificity, overall discrimination between BRCA gene mutation carriers and BRCA gene mutation noncarriers was slightly better for BRCAPRO.
Keywords
Biochemistry, Genetics and Molecular Biology
BiometricsComparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach
22,316 Citations1988Elizabeth R. DeLong, David M. DeLong +1 more
A nonparametric approach to the analysis of areas under correlated ROC curves is presented, by using the theory on generalized U-statistics to generate an estimated covariance matrix.
The American Journal of Human GeneticsGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
3,047 Citations1998Deborah Ford, Douglas F. Easton +36 more
The lifetime risk of breast cancer appears similar to the risk in BRCA1 carriers, but there was some suggestion of a lower risk in bRCA2 carriers <50 years of age.
New England Journal of MedicineThe Risk of Cancer Associated with Specific Mutations of<i>BRCA1</i>and<i>BRCA2</i>among Ashkenazi Jews
2,262 Citations1997Jeffery P. Struewing, Patricia Hartge +7 more
The risks of breast cancer may be overestimated, but they fall well below previous estimates based on subjects from high-risk families.
The LancetRisks of cancer in BRCA1-mutation carriers
1,866 Citations1994Daniel Ford
Estimates of breast and ovarian cancer risks are provided which are useful for counselling BRCA1-mutation carriers and carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.
PubMedBreast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
1,587 Citations1995Douglas F. Easton, Deborah Ford +1 more
Data from families with evidence of linkage to BRCA1 is used to estimate the age-specific risks of breast and ovarian cancer in BRCa1-mutation carriers and to examine the variation in risk between and within families.
New England Journal of MedicineBreast Cancer after Prophylactic Bilateral Mastectomy in Women with a<i>BRCA1</i>or<i>BRCA2</i>Mutation
963 Citations2001Hanne Meijers-Heijboer, Bert van Geel +10 more
In women with a BRCa1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.
The American Journal of Human GeneticsDetermining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
760 Citations1998Giovanni Parmigiani, Donald A. Berry +1 more
A model for evaluating the probabilities that a woman is a carrier of a mutation of BRCA1 and BRCa2, on the basis of her family history of breast and ovarian cancer in first- and second-degree relatives is developed.
JNCI Journal of the National Cancer InstituteEfficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
745 Citations2001Lynn C. Hartmann, Thomas A. Sellers +13 more
New England Journal of Medicine<i>BRCA1</i>Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
681 Citations1997Fergus J. Couch, Michelle L. DeShano +11 more
The results suggest that even in a referral clinic specializing in screening women from high-risk families, the majority of tests for BRCA1 mutations will be negative and therefore uninformative.
JNCI Journal of the National Cancer InstituteBreast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
678 Citations1999Timothy R. Rebbeck, Albert M. Levin +13 more
Bilateral prophylactic oophorectomy is associated with a reduced breast cancer risk in women who carry a BRCA1 mutation, and the likely mechanism is reduction of ovarian hormone exposure.
Nature GeneticsBRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
446 Citations1997Anne Petrij-Bosch, Tamara Peelen +16 more
It is reported that the currently available mutation spectrum of BRCA1 has been biased by PCR-based mutation-screening methods, such as SSCP, the protein truncation test (PTT) and direct sequencing, using genomic DMA as template.
The American Journal of Human GeneticsCancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
390 Citations1997Douglas F. Easton, Linda Steele +11 more
The results indicate that the lifetime breast cancer risk in BRCA2 carriers, for at least a subset of mutations, is comparable to that for BRCa1.
JNCI Journal of the National Cancer InstituteProbability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History
383 Citations1997D. A. Berry, Giovanni Parmigiani +3 more
A mathematic model is developed and applied for calculating the probability that a woman with a family history of breast and/or ovarian cancer carries a mutation of BRCA1, and assumes that all other breast cancer is sporadic.
JAMABRCA1 Sequence Analysis in Women at High Risk for Susceptibility Mutations
378 Citations1997Donna Shattuck-Eidens
Using logistic regression analysis, this work provides a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.
PubMedFounder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
321 Citations1997Ephrat Levy‐Lahad, Raphael Catane +9 more
The high rate of germ-line BRCA1/BRCA2 mutations in Ashkenazi women and families with ovarian cancer is coupled with penetrance that is lower than previously estimated.
The American Journal of Human GeneticsBRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
320 Citations2000Roxana Moslehi, William Chu +15 more
Only one nonfounder mutation was identified (in this instance, in a woman of mixed ancestry), and the three founding mutations accounted for most of the observed excess risk of ovarian and breast cancer in relatives.
UCL Discovery (University College London)Breast and ovarian cancer incidence in BRCA1-mutation carriers
301 Citations1995Easton, D F, Ford, D +5 more
PubMedStudy of a single BRCA2 mutation with high carrier frequency in a small population.
299 Citations1997Steinunn Thorlacius, Stefán Sigurðsson +6 more
Comparison of the age at onset for mother/daughter pairs with the 999del5 mutation and breast cancer indicates thatAge at onset is decreasing in the younger generation, and increase in breast cancer incidence and lower age at inception suggest a possible contributing environmental factor.
The American Journal of Human GeneticsThe Prevalence of Common BRCA1 and BRCA2 Mutations among Ashkenazi Jews
226 Citations1999Patricia Hartge, Jeffery P. Struewing +3 more
In men and in women never given a diagnosis of cancer, family history of breast cancer before age 50 years was the strongest predictor of mutation status, and fewer mutations were found in this community sample than in clinical series studied to date.
Genetic EpidemiologyRisk models for familial ovarian and breast cancer
187 Citations2000Antonis C. Antoniou, S. Gayther +3 more
BRCA1 and BRCA2 may be sufficient to explain the majority of familial ovarian cancer and that families without mutations can be explained by sensitivity of mutation testing and chance clusters of sporadic cases.
PubMedA 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17.
178 Citations1997Nadine Puget, Delphine Torchard +5 more
Re rearrangements in the BRCA1 gene should be sought in breast/ovarian cancer families in which no mutations have been found by PCR-based methods in the coding region or in the splice sites.
PubMedBRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
167 Citations1997Elizabeth L. Schubert, M K Lee +6 more
In order to evaluate the role of inherited BRCA2 mutations in American families--particularly the appearance in America of European founder mutations--the B RCA2 coding sequence, 5' UTR, and 3' U TR were screened in 22 Caucasian American kindreds with four or more cases of breast or ovarian cancer.
American Journal of EpidemiologyThe Kin-Cohort Study for Estimating Penetrance
144 Citations1998Sholom Wacholder, Patricia Hartge +5 more
The kin-cohort design can be a useful tool for quickly estimating penetrance from volunteers in a setting in which the mutation prevalence is relatively high.
Europe PMC (PubMed Central)Study of a single BRCA2 mutation with high carrier frequency in a small population.
131 Citations1997Thorlacius, S, Sigurdsson, S +6 more
Clinical GeneticsA preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center
114 Citations2000CA Gilpin, Nancy Carson +1 more
In this population, a family history assessment tool (FHAT) was effective in minimizing both the number of referrals and the likelihood of missing women who were later found to be mutation‐positive.
British Journal of CancerA probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families
108 Citations2001Pia Vahteristo, Hannaleena Eerola +3 more
The probability model should be a useful tool in genetic counselling and focusing the mutation analyses, and thus increasing also the cost-effectiveness of the genetic screening.
British Journal of CancerCharacteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
46 Citations1999Marjolijn J. L. Ligtenberg, Frans B.L. Hogervorst +17 more
Even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.
Genetic TestingBRCA1 and BRCA2 Mutations in Ashkenazi Jewish Families with Breast and Ovarian Cancer
35 Citations1997Elizabeth L. Schubert, Heather C Mefford +4 more
Almost half of Ashkenazi Jewish families with four or more cases of breast and ovarian cancer cannot be accounted for by either the ancient or novel mutations, suggesting the possibility of novel mutation, either in BRCA1, BRCa2, or in currently unidentified gene(s), responsible for the remainder.
The American Journal of Human GeneticsPenetrances of BRCA1 1675delA and 1135insA with Respect to Breast Cancer and Ovarian Cancer
27 Citations1999Anne Dørum, Ketil Heimdal +3 more
The overall findings were that disease started to occur at age 30 years and that by age 50 years 48% of the mutation-carrying women had experienced breast and/or ovarian cancer, and more ovarian cancers than breast cancers were recorded.